SBX.DE SynBiotic SE (XETRA) down 17.59% intraday: watch cash runway
SBX.DE stock fell 17.59% intraday on XETRA to €2.60 on 09 Jan 2026, marking it among today’s top losers. Volume jumped to 21,451.00 shares versus an average of 7,639.00, signalling active selling. The drop follows weak near-term liquidity metrics and continued losses on the income statement. Traders should note SynBiotic SE’s current market cap of €18,722,487.00 and a trailing EPS of -2.24, which tie company fundamentals to the intraday sell-off.
SBX.DE stock intraday price action and volume
SynBiotic SE (SBX.DE) opened at €2.46 and hit a day low of €2.37 before stabilising near €2.60. The stock fell €0.55 on the session, a -17.59% move versus the prior close of €3.16. Trading volume was 21,451.00, a 2.81x rise on the average daily volume of 7,639.00, indicating outsized flows and likely stop-driven selling. This price action places SBX.DE among intraday top losers on XETRA for 09 Jan 2026.
Drivers and recent SBX.DE stock news
There is no single headline in today’s data feed, but market attention has focused on sector comparisons and company metrics. Investors are reviewing SynBiotic’s competitive standing within the healthcare/drug manufacturers group. For a peer comparison view see Investing.com comparison of SynBiotic SE. The intraday move likely reflects positioning ahead of the next earnings announcement and tighter sentiment around small-cap biotech names.
SBX.DE stock fundamentals and valuation
SynBiotic’s trailing EPS is -2.24 and the reported P/E is -1.48, reflecting persistent losses. Key ratios include a price-to-book of 0.99 and price-to-sales of 4.85. The company shows a current ratio of 0.81 and cash per share of €0.59, highlighting a constrained short-term liquidity profile. Inventory days and payables days are stretched, with days of inventory on hand at 438.60 and days payable at 365.96, which pressure working capital and cash conversion.
SBX.DE stock technical snapshot
Momentum indicators show mixed signals: RSI 61.31 and MACD positive but narrow (MACD 0.24, signal 0.19). Trend strength is solid with ADX 33.03. Volatility sits higher with ATR 0.38 and MFI at 80.86, which reads as overbought on money flow despite the price drop. The 50-day average is €2.33 and the 200-day average is €2.88, showing the stock is trading below its longer-term average.
Meyka AI grade and SBX.DE stock forecast
Meyka AI rates SBX.DE with a score of 61.83 out of 100 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics and analyst consensus. Meyka AI’s forecast model projects a yearly price of €4.01, a projected upside of 54.16% versus today’s €2.60. Forecasts are model-based projections and not guarantees. Use the grade as a data point, not investment advice.
Trading considerations and risks for SBX.DE stock
Key risks include continued cash burn, negative operating margins, and thin market cap liquidity. SynBiotic’s market cap is €18,722,487.00 and shares outstanding are 5,647,809.00, which can amplify volatility on order flow. Sector risk for small-cap healthcare names remains elevated. On the opportunity side, a recovery towards the yearly high of €5.60 would imply material gains, but that relies on clinical or commercial progress that is not yet visible in today’s data.
Final Thoughts
SBX.DE stock’s -17.59% intraday move to €2.60 on XETRA reflects a mix of thin liquidity, weak short-term ratios and continued operating losses. Fundamentals show a trailing EPS of -2.24 and a constrained current ratio of 0.81, which explains why small negative signals can trigger sharp drops. Meyka AI’s forecast model projects a yearly target of €4.01, implying an upside of 54.16% from today’s price. That projection is model-driven and contrasts with longer-term uncertainty, such as stretched inventory days and negative cash flow per share. For traders, watch intraday liquidity, bid-ask spreads and the next earnings update. For investors, weigh the B grade and model forecasts against cash runway and sector dynamics before adding exposure. Forecasts are model-based projections and not guarantees.
FAQs
What caused the SBX.DE stock drop today?
The intraday fall to €2.60 reflects weak short-term liquidity, larger-than-normal selling volume of 21,451.00 shares, and concern over negative earnings metrics such as EPS -2.24 and current ratio 0.81.
What is the Meyka AI view on SBX.DE stock?
Meyka AI gives SBX.DE a score of 61.83/100 (Grade B, HOLD). The model highlights mixed fundamentals and a model-based yearly forecast of €4.01, with a 54.16% implied upside from €2.60.
Is SBX.DE stock a value or a growth play?
SynBiotic sits in healthcare as an early-stage specialty drug maker. Valuation shows a price-to-book near 0.99 but losses on the income statement, making it a speculative growth play with value-like balance-sheet caveats.
What should traders watch next for SBX.DE stock?
Monitor intraday volume, bid-ask spreads, the 50-day and 200-day averages (€2.33 and €2.88), and any news around product development or funding that could change liquidity and sentiment.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
